The pillars that make a randomized trial credible
Randomization assigns participants to treatment or control by chance, which on average balances both known and unknown confounders between the groups so that differences in outcome can be attributed to the intervention. Allocation concealment, keeping the upcoming assignment hidden from those enrolling participants, protects this balance from being subverted at the point of entry.
Blinding then keeps participants, clinicians, and assessors unaware of who received what, limiting placebo effects and biased outcome judgement. A concurrent control arm provides the counterfactual: what would have happened without the intervention. Together these features are why a well-conducted RCT sits near the top of the evidence hierarchy for questions about treatment effect.
Why intention-to-treat is the honest analysis
Intention-to-treat analyses participants in the group they were randomized to, regardless of whether they completed or even started the assigned treatment. This preserves the benefit of randomization and reflects real-world effectiveness, because dropping non-adherers (a per-protocol analysis) can quietly reintroduce the confounding that randomization was meant to remove.
RCTs are not infallible: they can be underpowered, have limited follow-up, or enrol participants unlike the broader population. This is general educational information about study design, not medical advice.